MedTrace Logo

Augmenting Massed Prolonged Exposure With a Stellate Ganglion Block to Treat PTSD

NCT04302181 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-09-09

No results posted yet for this study

Summary

This is a small, open-label treatment study that tests the potential safety and treatment effectiveness of a stellate ganglion block combined with Massed Prolonged Exposure (PE). Each of the 12 participants will receive ten 90-minute sessions of Massed Prolonged Exposure and an injection of a stellate ganglion block between the first and second PE sessions.

Conditions

  • Stress Disorders, Post-Traumatic

Interventions

DRUG

Ropivacaine injection

6.5cc of Ropivacaine HCl 0.5%, one time into the stellate ganglion

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • The University of Texas Health Science Center at San Antonio

    lead OTHER

Principal Investigators

  • Alan Peterson, PhD, ABPP · University of Texas Health San Antonio Texas at San Antonio

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-05
Primary Completion
2021-07-01
Completion
2021-12-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04302181 on ClinicalTrials.gov